QIAGEN opens New Service Solutions Center in Asia

State of the art facility completes global customer care network and
supports further expansion in the region


Venlo, The  Netherlands /  Singapore  - February  22, 2008  -  QIAGEN
(Nasdaq: QGEN; Frankfurt,  Prime Standard:  QIA) today  opened a  new
Service Solutions Center  in Singapore for  the Asia-Pacific  region.
The facility completes the Company's global Service Solution  Network
by adding a center in the Asia-Pacific region to its existing centers
in the  United  States  (Valencia, CA  and  Germantown,  MD),  Europe
(Hilden, Crawley,  Paris) and  Japan  (Tokyo). By  the end  of  2008,
QIAGEN's global customer support  network will provide  comprehensive
solutions-oriented service to customers at  any time in any place  in
the world.

The new center will further increase the Company's responsiveness  to
the information and  service requirements of  customers in  research,
applied testing,  pharma  and  molecular diagnostics  in  the  entire
Asian-Pacific region including Australia, allowing them to access the
Company's services faster,  more conveniently  and more  efficiently.
The facility  will serve  as a  base for  QIAGEN employees  who  will
handle customer  care  and  technical service  requests  in  regional
languages including Korean, Mandarin, Cantonese, Malay and English.

"QIAGEN not  only sets  standards in  the development  of  innovative
sample and assay  technologies, but also  for delivering  outstanding
service solutions", said Peer M. Schatz, CEO of QIAGEN who hosted the
official opening in  Singapore. "With this  investment we can  better
respond to the  needs of  each and every  customer, and  we can  also
extend our services  to 24 hours  a day, 7  days a week  in the  near
future. It moves us  even closer to our  customers in all our  market
segments and helps  us extend  our global reach  and enhance  service
level in this fast growing region."

"We are pleased that QIAGEN has chosen Singapore for its new  Service
Solutions Center,  just after  its recent  announcement to  set up  a
molecular diagnostics R&D center  here. This reinforces Singapore  as
an excellent location to effectively engage in the fast growing  Asia
Pacific healthcare market," said Ms  Aw Kah Peng, Assistant  Managing
Director, Singapore Economic Development Board. "We will continue  to
invest in translational  research capabilities,  particularly in  the
area  of  diagnostics,  to  further  sharpen  Singapore's  innovative
approach towards biomedical research and affordable healthcare."

The new  center  complements  QIAGEN's recent  major  initiatives  in
Singapore. In December  2007, the  Company opened DX  Assay, a  joint
venture with Bio*One Capital. DX Assay develops molecular  diagnostic
tests which impact how diseases are detected and treated. In  January
2008, QIAGEN announced that it had been awarded an exclusive contract
by the  Singapore Ministry  of Health  to supply  sample  preparation
solutions and  molecular  test kits  for  the specific  detection  of
Influenza H5N1 viruses -  better known as  avian flu. QIAGEN  employs
more than 50 staff in Singapore.


About QIAGEN Asia
With growth rates  of 50  per cent,  Asia today  is QIAGEN's  fastest
growing market, with Singapore  taking significant market share.  The
Company's strategic expansion  into the region  began in 2005.  Today
QIAGEN maintains  7 Asian  offices encompassing  locations in  China,
Korea, Malaysia, Hong  Kong and Singapore,  with over 370  employees.
Including the subsidiary in  Japan, they contribute approximately  15
per cent to QIAGEN's overall net sales. In 2006, QIAGEN received  the
Frost  &  Sullivan  Award  for  Competitive  Strategy  Leadership  in
recognition  of  its  strategic  initiatives  in  the  Asia   Pacific
molecular testing market.

About QIAGEN
QIAGEN N.V., a Netherlands holding company is the leading provider of
innovative sample  and  assay  technologies  and  products.  QIAGEN's
products are  considered standards  in areas  such as  pre-analytical
sample preparation and assay solutions in research for life sciences,
applied testing  and molecular  diagnostics. QIAGEN  has developed  a
comprehensive portfolio  of  more than  500  proprietary,  consumable
products and automated solutions for sample collection, nucleic  acid
and protein  handling,  separation,  and purification  and  open  and
target specific  assays.  QIAGEN's  products  are  sold  to  academic
research  markets,  to   leading  pharmaceutical  and   biotechnology
companies, to  applied  testing  customers  (such  as  in  forensics,
veterinary, biodefense  and industrial  applications) as  well as  to
molecular diagnostics laboratories.  QIAGEN employs  more than  2,600
people worldwide. QIAGEN products are sold through a dedicated  sales
force and a global network of distributors in more than 40 countries.
In this press release QIAGEN is using the term molecular diagnostics.
The use of this  term is in reference  to certain countries, such  as
the  United  States,  limited  to  products  subject  to   regulatory
requirements. Current QIAGEN molecular diagnostics products are 34 EU
CE IVD assays, six  EU CE IVD sample  preparation products, one  510k
PAX RNA product, nine  China SFDA IVD assays  and 98 general  purpose
reagents.  Further  information   about  QIAGEN  can   be  found   at
www.qiagen.com.


Forward-Looking Statements
Certain of  the statements  contained  in this  news release  may  be
considered forward-looking statements within  the meaning of  Section
27A of the U.S. Securities Act  of 1933, as amended, and Section  21E
of the  U.S. Securities  Exchange Act  of 1934,  as amended.  To  the
extent that  any  of  the statements  contained  herein  relating  to
QIAGEN's  products,  markets,  strategy  or  operating  results   are
forward-looking, such statements  are based  on current  expectations
that involve a number of uncertainties and risks. Such  uncertainties
and risks  include, but  are not  limited to,  risks associated  with
management of  growth  and international  operations  (including  the
effects  of  currency  fluctuations   and  risks  of  dependency   on
logistics),  variability   of  operating   results,  the   commercial
development of the applied testing markets, clinical research markets
and proteomics  markets,  nucleic  acid-based  molecular  diagnostics
market,  and   genetic   vaccination  and   gene   therapy   markets,
competition,   rapid   or   unexpected   changes   in   technologies,
fluctuations in demand for QIAGEN's, products (including fluctuations
due to the level and timing of customers' funding, budgets, and other
factors), our ability to obtain regulatory approval of our infectious
disease  panels,  difficulties  in  successfully  adapting   QIAGEN's
products to  integrated solutions  and producing  such products,  the
ability of  QIAGEN  to  identify  and develop  new  products  and  to
differentiate  its  products   from  competitors'  products,   market
acceptance of QIAGEN's new products  and the integration of  acquired
technologies and businesses.  For further information,  refer to  the
discussions in reports that QIAGEN  has filed with, or furnished  to,
the U.S. Securities and Exchange Commission (SEC).

                                 ###

Contacts:

Public Relations:                            For Singapore / China :

Phone:    Europe: [phone]          Tel:     [phone]
              US: [phone]            Email: [e-mail]
Email:     [e-mail]

Investor Relations:

Phone:    Europe:  [phone]
               US:       [phone]
Email:      [e-mail]